title: Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY.
abstract: OBJECTIVE
  The role of the novel adipokines, omentin-1 and chemerin, in coronary artery disease is still obscure. The present study analyzed the serum levels of omentin-1 and chemerin in patients with acute myocardial infarction (AMI) as well as prospectively 6 months post-AMI.
  
  
  METHODS
  Seventy-eight patients (63 men and 15 women) with first AMI were enrolled. Thirty-two age-matched and sex-matched individuals without overt cardiovascular disease served as healthy controls. Serum levels of omentin-1, chemerin, interleukin-18 (IL-18), high-sensitivity C-reactive protein (hsCRP), glycemic and lipid profiles, blood pressure, BMI and ejection fraction were assayed. In AMI patients, blood samples were obtained at hospital admission and after 6 months, whereas coronary angiography was performed within 7 days after admission.
  
  
  RESULTS
  At baseline, AMI group appeared with significantly lower ejection fraction, omentin-1 and high-density lipoprotein serum levels, whereas it had higher concentrations of white blood cells count (WBC), hsCRP, IL-18 and chemerin compared with healthy controls (P < 0.05). After 6 months of follow-up, the concentrations of WBC, hsCRP and IL-18 significantly downregulated, whereas omentin-1 levels considerably increased (from 18.73 ± 3.66 ng/ml to 28.62 ± 5.61 ng/ml, P < 0.001) within AMI group. In contrast, serum chemerin did not significantly change (263.37 ± 73.32 ng/ml vs. 195.90 ± 84.32 ng/ml, P = 0.190). In standard multiple regression analyses, baseline levels and changes of hsCRP and IL-18 levels during follow-up remained independent determinants of omentin-1, respectively at baseline and after follow-up.
  
  
  CONCLUSIONS
  Patients with AMI showed at admission lower omentin-1 and higher chemerin serum levels compared with healthy controls. The suppression of inflammation in the 6-month post-AMI period might have mediated the significant upregulation of omentin-1, implicating a novel target of treatment.
authors.affiliation: a2nd Department of Cardiology, 'Attikon' University Hospital, Athens bDepartment of Cardiology, 'Mamatsio' General Hospital, Kozani cCenter of Experimental Surgery, Biomedical Research Foundation, Academy of Athens, Greece.
authors.forename: Nikolaos P E
authors.initials: NP
authors.lastname: Kadoglou
authors.forename: Dimitrios K
authors.initials: DK
authors.lastname: Tahmatzidis
authors.forename: Christos
authors.initials: C
authors.lastname: Giannakoulas
authors.forename: Alkistis
authors.initials: A
authors.lastname: Kapelouzou
authors.forename: Argirios
authors.initials: A
authors.lastname: Gkontopoulos
authors.forename: John
authors.initials: J
authors.lastname: Parissis
authors.forename: Stylianos
authors.initials: S
authors.lastname: Lampropoulos
authors.forename: George
authors.initials: G
authors.lastname: Kottas
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D018925:Chemokines / Q000097:blood*; D016207:Cytokines / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D058851:GPI-Linked Proteins / Q000097:blood; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D020382:Interleukin-18 / Q000097:blood; D037102:Lectins / Q000097:blood*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000628:therapy
chemical_list: D015415:Biomarkers; D018925:Chemokines; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D018836:Inflammation Mediators; D036341:Intercellular Signaling Peptides and Proteins; D020382:Interleukin-18; D037102:Lectins; D008055:Lipids; C478630:RARRES2 protein, human; D002097:C-Reactive Protein